Results: 3

1.
Figure 2

Figure 2. From: Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Differential expression of eight top ranking novel markers (CCND1, CRMP1, DDC, GABRB3, ISL1, KIF1A, PHOX2B, TACC2) and TH in 20 stage 4 NB tumors and 20 normal mononuclear cells. Tumors in gray, normal mononuclear cells in black, and transcript units in log (10) scale.

Irene Y. Cheung, et al. Clin Cancer Res. ;14(21):7020-7027.
2.
Figure 3

Figure 3. From: Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Kaplan-Meier plots of progression-free survival for the eight top ranking novel markers (CCND1, CRMP1, DDC, GABRB3, ISL1, KIF1A, PHOX2B, TACC2) with respect to marker status. Open circle: marker positive, vertical line: marker negative. Except for CRMP1 and TACC2, these markers were highly prognostic of outcome (p<0.001).

Irene Y. Cheung, et al. Clin Cancer Res. ;14(21):7020-7027.
3.
Figure 1

Figure 1. From: Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma.

Sensitivity of novel markers CRMP1, DDC, GABRB3, ISL1, KIF1A, and PHOX2B was evaluated by seeding NB cell line LAN1 and NMB7, ranging from 1 to 104 cells in 107 normal mononuclear cells (MNC). Gene expression level of 104 tumor cells in 107 normal MNC was defined as 1000 units. Quantitation was based on mean + S.D. of 3 experiments.

Irene Y. Cheung, et al. Clin Cancer Res. ;14(21):7020-7027.

Supplemental Content

Recent activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...
Write to the Help Desk